Current advances in targeted therapies for metastatic gastric cancer: Improving patient care

Future Oncology

Volumn 12, Issue 6, 2016, Pages 839-854

  Aguiar, Pedro Nazareth ^a   Muniz, Thiago Pimentel ^a   Miranda, Raelson Rodrigues ^a   Tadokoro, Hakaru ^a   Forones, Nora Manoukian ^a   Monteiro, Ines De Paula ^b   Castelo Branco, Pedro ^c   Janjigian, Yelena Y ^d   De Mello, Ramon Andrade ^b,c,e  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b University of Porto   (Portugal)

^c UNIVERSITY OF ALGARVE   (Portugal)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Instituto do Cancer do Ceara   (Brazil)

Author keywords

current advances; gastric cancer; gastric cancer therapy; patient care; targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; APATINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MATUZUMAB; ONARTUZUMAB; PANITUMUMAB; PAZOPANIB; PERTUZUMAB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CANCER THERAPY; DRUG EFFICACY; DRUG TARGETING; HUMAN; METASTASIS; NONHUMAN; OVERALL SURVIVAL; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; STOMACH CANCER; STOMACH TUMOR; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; STOMACH NEOPLASMS; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PATIENT CARE; PROTEIN KINASE INHIBITORS; QUALITY IMPROVEMENT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84959319260     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.348     Document Type: Review

References (82)

1. Cancer IaFRO, Organization WH. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan. iarc. fr
2. Inca. Estimativas para o ano de 2014 das taxas brutas de incidência por 100 mil habitantes e do número de casos novos de câncer, segundo sexo e localização primária. www. saude. sp. gov. br
3. Society AC. Cancer Facts & Figures 2015. www. cancer. org
4. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72(1), 37-41 (1993).
5. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358(1), 36-46 (2008).
6. Kang YK, Kang WK, Shin DB et al. Capecitabine/cisplatin versus 5-fluorouracil/ cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised Phase III noninferiority trial. Ann. Oncol. 20(4), 666-673 (2009).
7. Guimbaud R, Louvet C, Ries P et al. Prospective, randomized, multicenter, Phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J. Clin. Oncol. 32(31), 3520-3526 (2014).
8. De Vita F, Di Martino N, Fabozzi A et al. Clinical management of advanced gastric cancer: the role of new molecular drugs. World J. Gastroenterol. 20(40), 14537-14558 (2014).
9. Shah MA, Khanin R, Tang L et al. Molecular classification of gastric cancer: a new paradigm. Clin. Cancer. Res. 17(9), 2693-2701 (2011).
10. Bickenbach K, Strong VE. Comparisons of gastric cancer treatments: east vs. west. J. Gastric Cancer 12(2), 55-62 (2012).
11. Gravalos C, Márquez A, García-Carbonero R, Rivera F, Colomer R, Sastre J. Correlation between Her2/neu overexpression/ amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study. Presented at: Gastrointestinal Cancers Symposium 2007. Orlando, FL, USA, 19-21 January 2007.
12. Lieto E, Ferraraccio F, Orditura M et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann. Surg. Oncol. 15(1), 69-79 (2008).
13. Carneiro F, Huntsman DG, Smyrk TC et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J. Pathol. 203(2), 681-687 (2004).
14. Tuccillo C, Cuomo A, Rocco A et al. Vascular endothelial growth factor and neoangiogenesis in H. pylori gastritis in humans. J. Pathol. 207(3), 277-284 (2005).
15. Luis M, Tavares A, Carvalho LS, Lara-Santos L, Araújo A, De Mello RA. Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies. World J. Gastroenterol. 19(38), 6383-6397 (2013).
16. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
17. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet 376(9742), 687-697 (2010).
18. Cortés-Funes H, Rivera F, Alés I et al. Phase II of trastuzumab and cisplatin in patients with advanced gastric cancer with HER2/neu overexpression/amplification. J. Clin. Oncol. 25, 4613 (2007).
19. Egamberdiev D, Djuraev M, Tuydjanova K, Nematov O. Our experience in the use of trastuzumab in patients with advanced stomach cancer. Ann. Oncol. 21(Suppl. 8), S839 (2010).
20. Grávalos C, Gómez-Martín C, Rivera F et al. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin. Transl. Oncol. 13(3), 179-184 (2011).
21. Kang YK, Rha SY, Tassone P et al. A Phase IIa dose-finDing and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Br. J. Cancer 111(4), 660-666 (2014).
22. Iqbal S, Goldman B, Lenz H, Fenoglio-Preiser C, Blanke C. S0413: a Phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer. Presented at: 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL, USA, 1-5 June 2007.
23. Hecht J, Bang Y, Qqin S, Al E. Lapatinib in combination with capecitabine plus oxaliplatin (CAPOX) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: the TRIO-013/LOGiC trial. Presented at: ASCO Annual Meeting 2013. Chicago, IL, USA, 31 May-4 June 2013.
24. Galsky MD, Von Hoff DD, Neubauer M et al. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest. New Drugs 30(2), 695-701 (2012).
25. Satoh T, Xu RH, Chung HC et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN-a randomized, Phase III study. J. Clin. Oncol. 32(19), 2039-2049 (2014).
26. Rech J, Arnold D, Folprecht G. A pilot study of trastuzumab monotherapy in patients whoprogressed while on chemotherapy for metastatic or locally advanced HER-2 positive gastric cancer. Presented at: ESMO 2006 The European Society for Medical Oncology. Istanbul, Turkey, 29 September-3 October 2006.
27. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367(19), 1783-1791 (2012).
28. Clinical Trial Database: NCT01641939. https://clinicaltrials.gov
29. Yamashita-Kashima Y, Iijima S, Yorozu K et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin. Cancer. Res. 17(15), 5060-5070 (2011).
30. Clinical Trial Database: NCT01774786. https://clinicaltrials.gov
31. Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17(3), 471-494 (2014).
32. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog. Horm. Res. 55, 15-35; discussion 5-16 (2000).
33. Stoeltzing O, Mccarty MF, Wey JS et al. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J. Natl Cancer Inst. 96(12), 946-956 (2004).
34. Partyka R, Gonciarz M, Ja?owiecki P, Kokoci?ska D, Byrczek T. VEGF and metalloproteinase 2 (MMP 2) expression in gastric cancer tissue. Med. Sci. Monit. 18(4), BR130-BR134 (2012).
35. Schimanski CC, Schlaegel F, Jordan M et al. VEGF-D correlates with metastatic disease in gastric cancer patients undergoing surgery. World J. Surg. 35(5), 1010-1016 (2011).
36. Shah MA, Ramanathan RK, Ilson DH et al. Multicenter Phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol. 24(33), 5201-5206 (2006).
37. Shah MA, Jhawer M, Ilson DH et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J. Clin. Oncol. 29(7), 868-874 (2011).
38. Uronis HE, Bendell JC, Altomare I et al. A Phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. Oncologist 18(3), 271-272 (2013).
39. El-Rayes BF, Zalupski M, Bekai-Saab T et al. A Phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann. Oncol. 21(10), 1999-2004 (2010).
40. Shen L, Li J, Xu J et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, Phase III study (AVATAR study). Gastric Cancer 18(1), 168-176 (2015).
41. Ohtsu A, Shah MA, Van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled Phase III study. J. Clin. Oncol. 29(30), 3968-3976 (2011).
42. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J. Clin. Oncol. 28(18), 2947-2951 (2010).
43. Martin-Richard M, Gallego R, Pericay C et al. Multicenter Phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest. New Drugs 31(6), 1573-1579 (2013).
44. Moehler M, Mueller A, Hartmann JT et al. An open-label, multicentre biomarkeroriented AIO Phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur. J. Cancer 47(10), 1511-1520 (2011).
45. Bang YJ, Kang YK, Kang WK et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest. New Drugs 29(6), 1449-1458 (2011).
46. Yoon H, Bendell J, Braiteh F et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter Phase 2 trial. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting 2014 Chicago, IL, USA 30 May-3 June 2014 (Abstract 4004).
47. Wilke H, Muro K, Van Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised Phase 3 trial. Lancet Oncol. 15(11), 1224-1235 (2014).
48. Fuchs CS, Tomasek J, Yong CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, Phase 3 trial. Lancet 383(9911), 31-39 (2014).
49. Qin S. Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial. Presented at: ASCO American Society of Clinical Oncology (ASCO) Annual Meeting 2014 Chicago, IL, USA, 30 May-3 June 2014 (Abstract 4003).
50. Clinical trials database: NCT01503372. https://clinicaltrials.gov
51. Clinical trials database: NCT01130805. https://clinicaltrials. Gov
52. Ayyappan S, Prabhakar D, Sharma N. Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer. Anticancer Res. 33(10), 4139-4155 (2013).
53. Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol. Res. 79 34-74 (2014).
54. Kasper S, Schuler M. Targeted therapies in gastroesophageal cancer. Eur. J. Cancer 50(7), 1247-1258 (2014).
55. Pinto C, Di Fabio F, Siena S et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann. Oncol. 18(3), 510-517 (2007).
56. Pinto C, Di Fabio F, Barone C et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastrooesophageal junction adenocarcinoma (DOCETUX study). Br. J. Cancer 101(8), 1261-1268 (2009).
57. Lordick F, Luber B, Lorenzen S et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a Phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br. J. Cancer 102(3), 500-505 (2010).
58. Moehler M, Mueller A, Trarbach T et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented Phase II study. Ann. Oncol. 22(6), 1358-1366 (2011).
59. Kim C, Lee JL, Ryu MH et al. A prospective Phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest. New Drugs 29(2), 366-373 (2011).
60. Richards D, Kocs DM, Spira AI et al. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. Eur. J. Cancer 49(13), 2823-2831 (2013).
61. Chan JA, Blaszkowsky LS, Enzinger PC et al. A multicenter Phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann. Oncol. 22(6), 1367-1373 (2011).
62. Lordick F, Kang YK, Chung HC et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label Phase 3 trial. Lancet Oncol. 14(6), 490-499 (2013).
63. Rao S, Starling N, Cunningham D et al. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br. J. Cancer 99(6), 868-874 (2008).
64. Rao S, Starling N, Cunningham D et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label Phase II study. Ann. Oncol. 21(11), 2213-2219 (2010).
65. Waddell T, Verheij M, Allum W et al. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl. 6), vi57-vi63 (2013).
66. Rodriguez CP, Adelstein DJ, Rice TW et al. A Phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J. Thorac. Oncol. 5(2), 229-235 (2010).
67. Dragovich T, Mccoy S, Fenoglio-Preiser CM et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J. Clin. Oncol. 24(30), 4922-4927 (2006).
68. Wainberg ZA, Lin LS, Dicarlo B et al. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br. J. Cancer 105(6), 760-765 (2011).
69. Okines AF, Ashley SE, Cunningham D et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finDing study for the prospective multicenter, randomized, Phase II/III REAL-3 trial. J. Clin. Oncol. 28(25), 3945-3950 (2010).
70. Rojo F, Tabernero J, Albanell J et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J. Clin. Oncol. 24(26), 4309-4316 (2006).
71. Shitara K, Doi T, Ohtsu A. Molecular targeting therapy and biomarker for advanced gastric cancer. J. Phys. Chem. Biophys. 2,6 (2012).
72. Lang SA, Gaumann A, Koehl GE et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int. J. Cancer 120(8), 1803-1810 (2007).
73. Doi T, Muro K, Boku N et al. Multicenter Phase II study of everolimus in patients with previously treated metastatic gastric cancer. J. Clin. Oncol. 28(11), 1904-1910 (2010).
74. Ohtsu A, Ajani JA, Bai YX et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, Phase III GRANITE-1 study. J. Clin. Oncol. 31(31), 3935-3943 (2013).
75. Clinical Trial Database: NCT01248403. https://clinicaltrials. Gov
76. Huang TJ, Wang JY, Lin SR, Lian ST, Hsieh JS. Overexpression of the c-MET protooncogene in human gastric carcinoma-correlation to clinical features. Acta Oncol. 40(5), 638-643 (2001).
77. Iveson T, Donehower RC, Davidenko I et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation Phase 1b study and a double-blind, randomised Phase 2 study. Lancet Oncol. 15(9), 1007-1018 (2014).
78. Shah M, Cho J, Huat J et al. Randomized Phase II study of FOLFOX +/-MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC). Presented at: 2015 Gastrointestinal Cancers Symposium (ASCO GI). San Francisco, CA, USA, 15-17 January 2015.
79. Clinical Trial Database: NCT01697072. https://clinicaltrials.gov
80. Chen DS, Irving BA, HoDi FS. Molecular pathways: next-generation immunotherapyinhibiting programmed death-ligand 1 and programmed death-1. Clin. Cancer Res. 18(24), 6580-6587 (2012).
81. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
82. Muro K, Bang Y, Shankaran V et al. LBA15 a Phase 1B study of pembrolizumab (pembro; MK-3475) in patients (pts) with advanced gastric cancer. Ann. Oncol. doi:10. 1093/ annonc/mdu438. 15 (2014) (Epub ahead of print).